IVIG (Intravenous Immunoglobulin) - Growth & Revenue Opportunities by Top Key Players of Market | Baxter international, Grifols, Octapharma, Kedrion Biopharma, Biotest, China Biologics Products, BDI Pharma & Bayer Healthcare

IVIG market (Intravenous Immunoglobulin Market) was valued at $7,861 million, and is expected to reach $12,632 million by 2022, supported by a CAGR of 7.1%. Immunoglobulins (IGs) are glycoproteins produced in the blood plasma in response to the antigens, which are foreign to the host system. They are highly complex entities and specific in their action. They are obtained from blood by fractionation process and purified for therapeutic and non-therapeutic applications. In therapeutics, they are administered intravenously in the treatment of various deficiencies.

Download [PDF] Report Sample @ https://www.alliedmarketresearch.com/request-sample/325

Key factors driving the market growth include approvals for IVIG therapy from FDA, EMA, and government, increase in awareness about IVIG treatment, rise in incidence of antibody deficiency diseases & hemophilic patients, and emergence of technologically advanced IVIG products. However, high cost products, side effects associated with its treatment, and stringent regulations restrict new product launch and hamper the IVIG market growth.

The hypogammaglobulinemia, CIDP, and immunodeficiency diseases segments together accounted for more than half market share in 2015, owing to high efficacy of IVIG treatment. Myasthenia gravis is the fastest growing segment, which is projected to grow at a CAGR of 10%.

Geographically, North America accounted for majority of the share, accounting for about 50% in 2015, and is expected to maintain its lead. This was attributed to the increased adoption of IVIG treatments, growth in incidence of immunodeficiency diseases, and high healthcare expenditure. However, regulatory framework concerns and limited IVIG products supply in North America adversely affect the market growth.

LAMEA is projected to grow at the highest CAGR of 10%, owing to the improving healthcare infrastructures and increasing expenditures in emerging markets to overcome the unmet medical needs in underdeveloped countries. Latin America led the market, with more than half of the LAMEA IVIG market share in 2015.

Key findings of IVIG Market:

- Specific antibody deficiency is the second fastest growing application in IVIG market, growing at a CAGR of 9% over the forecast period.

- The global IVIG market size accounted for 142 tons, in terms of volume, in 2015, and is expected to reach 236 tons by 2022, growing at a CAGR of 7%.

- Europe, the second fastest growing region, is expected to reach $3,000 million, in terms of value, by 2022.

Key players in the IVIG market focus on expanding their business operations in emerging countries, with new product launches as a preferred strategy. Leading companies profiled in this report include

- Baxter International Inc.,
- CSL Ltd.,
- Grifols S.A,
- Octapharma AG,
- Kedrion Biopharma Inc.,
- LFB group,
- Biotest AG,
- China Biologics Products, Inc.,
- BDI Pharma Inc., and Bayer Healthcare.

Get Customized Report @ https://www.alliedmarketresearch.com/request-for-customization/325

Table Of Content


Chapter: 1. INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS:
1.3. KEY MARKET SEGMENTS:
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst tools and models


Chapter: 2. EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3. MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. OVERVIEW OF IVIG

3.2.1. Patented products

3.3. EPIDEMIOLOGY AND ECONOMIC BURDEN OF CHRONIC CONDITIONS
3.4. COST OF SIDE EFFECTS DUE TO IVIG TREATMENTS
3.5. KEY FINDINGS

3.5.1. Top Factors Impacting global IVIG market
3.5.2. Top Investment PocketsGlobal IVIG Market

3.6. PORTERS FIVE FORCES ANALYSIS

3.6.1. Bargaining power of buyers (Low)
3.6.2. Bargaining power of suppliers (Low)
3.6.3. Threat of new entrants (low)
3.6.4. Threat of substitutes (low)
3.6.5. Intense competitive rivalry (moderate)

3.7. VALUE CHAIN ANALYSIS

3.7.1. Primary activities
3.7.2. Support Activities

3.8. MARKET SHARE ANALYSIS (2014)
3.9. PRODUCT SCENARIO IN IVIG MARKET
3.10. GOVERNMENT REGULATIONS AND REIMBURSEMENTS

3.10.1. IVIG regulations in United States and Europe
3.10.2. Reimbursements Scenario

3.11. INDICATIONS FOR IVIG

3.11.1. USFDA Indications

3.11.2. EMA

3.12. COMPONENT ANALYSIS OF IMMUNOGLOBULIN G (IGG)

3.12.1. IgG1
3.12.2. IgG2
3.12.3. IgG3
3.12.4. IgG4

3.13. CLINICAL TRIALS
3.15. MARKET DYNAMICS

3.15.1. Drivers
3.15.2. Restraints
3.15.3. Opportunities

Access Full Summery @ https://www.alliedmarketresearch.com/press-release/intravenous-immunoglobulin-IVIG-market.html

About Us

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.

Contact

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com

This release was published on openPR.